These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12441145)

  • 1. Immunopharmacology of recombinant human interleukin-18 in non-human primates.
    Herzyk DJ; Soos JM; Maier CC; Gore ER; Narayanan PK; Nadwodny KL; Liu S; Jonak ZL; Bugelski PJ
    Cytokine; 2002 Oct; 20(1):38-48. PubMed ID: 12441145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of natural antibodies to interleukin-18 in the sera of normal humans and three nonhuman primate species.
    Soos JM; Polsky RM; Keegan SP; Bugelski P; Herzyk DJ
    Clin Immunol; 2003 Nov; 109(2):188-96. PubMed ID: 14597217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical safety of recombinant human interleukin-18.
    Herzyk DJ; Bugelski PJ; Hart TK; Wier PJ
    Toxicol Pathol; 2003; 31(5):554-61. PubMed ID: 14692624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
    Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
    Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates.
    Schlerman FJ; Bree AG; Kaviani MD; Nagle SL; Donnelly LH; Mason LE; Schaub RG; Grupp SA; Goldman SJ
    Stem Cells; 1996 Sep; 14(5):517-32. PubMed ID: 8888493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
    J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates.
    Bree AG; Schlerman FJ; Kaviani MD; Hastings RC; Hitz SL; Goldman SJ
    Biochem Biophys Res Commun; 1994 Nov; 204(3):1150-7. PubMed ID: 7980590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombopoietic activity of recombinant human interleukin-11 in nonhuman primates with ACNU-induced thrombocytopenia.
    Saitoh M; Taguchi K; Yasuda S; Kikumori M; Nishimori T; Suda M; Okamiya H; Usuda S; Miyata K
    J Interferon Cytokine Res; 2000 Jun; 20(6):539-45. PubMed ID: 10888110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells.
    Bozza M; Bliss JL; Dorner AJ; Trepicchio WL
    J Interferon Cytokine Res; 2001 Jan; 21(1):21-30. PubMed ID: 11177577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant human interleukin 4 on human monocyte activity.
    Hudson MM; Markowitz AB; Gutterman JU; Knowles RD; Snyder JS; Kleinerman ES
    Cancer Res; 1990 Jun; 50(11):3154-8. PubMed ID: 2334911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.
    Keever-Taylor CA; Witt PL; Truitt RL; Ramanujam S; Borden EC; Ritch PS
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):231-43. PubMed ID: 8811498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I]recombinant human interleukin-2 in cynomolgus monkeys.
    Nadeau RW; Satoh H; Scheide S; Crowl R; Conroy R; Garland WA; Liberato DJ
    Drug Metab Dispos; 1995 Sep; 23(9):904-9. PubMed ID: 8565779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).
    Sarmiento UM; Riley JH; Knaack PA; Lipman JM; Becker JM; Gately MK; Chizzonite R; Anderson TD
    Lab Invest; 1994 Dec; 71(6):862-73. PubMed ID: 7807968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
    Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
    J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic growth-promoting effects of natural killer cells in mice in response to in vivo administration of human interleukin-2.
    Murphy WJ; Longo DL
    J Natl Cancer Inst; 1992 Aug; 84(15):1195-200. PubMed ID: 1635088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy.
    Olencki T; Finke J; Tubbs R; Tuason L; Greene T; McLain D; Swanson SJ; Herzog P; Stanley J; Edinger M; Budd GT; Bukowski RM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):69-80. PubMed ID: 8859726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pathologic alterations associated with subcutaneous administration of recombinant human interleukin-4 to cynomolgus monkeys.
    Gossett KA; Barbolt TA; Cornacoff JB; Zelinger DJ; Dean JH
    Toxicol Pathol; 1993; 21(1):46-53. PubMed ID: 8378706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of human recombinant IL-7 to normal and irradiated mice increases the numbers of lymphocytes and some immature cells of the myeloid lineage.
    Faltynek CR; Wang S; Miller D; Young E; Tiberio L; Kross K; Kelley M; Kloszewski E
    J Immunol; 1992 Aug; 149(4):1276-82. PubMed ID: 1500718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis.
    Drevlow BE; Lovis R; Haag MA; Sinacore JM; Jacobs C; Blosche C; Landay A; Moreland LW; Pope RM
    Arthritis Rheum; 1996 Feb; 39(2):257-65. PubMed ID: 8849376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of recombinant human interleukin-1 alpha in doxorubicin-treated normal and tumor-bearing mice.
    Lynch DH; Rubin AS; Miller RE; Williams DE
    Cancer Res; 1993 Apr; 53(7):1565-70. PubMed ID: 8453624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.